Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.

Abstract

BACKGROUND:

Prostate cancer (PCa) is a major type of cancer in man worldwide. Androgen deprivation therapy (ADT) and the next-generation androgen receptor (AR) pathway inhibitors have acquired great success in treating PCa. However, patients treated with ADT or AR targeted therapy are inevitably developing into castration-resistant prostate cancer (CRPC) or becoming drug resistance. The role of mRNA 5-methylcytosine (m5C) modification in cancers is largely unknown. This study aimed to explore the role of the m5C methyltransferase NSUN2 in Prostate cancer (PCa).

METHODS:

The expression of NSUN2 and its clinicopathological impact were evaluated in PCa cohorts. The effect of NSUN2 on the biological characteristics of PCa cells was investigated on the basis of gain-offunction and loss-of-function analyses. Subcutaneous models further uncovered the role of NSUN2 in tumor growth. Epi-transcriptome assays with RNA bisulfite sequencing (RNA-BisSeq) analysis and in vitro enzyme reaction assays were performed to validate the targeted effect of NSUN2 on AR. AR-binding sites in the NSUN2 promoter were investigated by ChIP and luciferase assays to uncover the interplay between NSUN2 and AR signaling. RIP-qPCR and EMSA methods were performed to confirm that YBX1 binds to AR m5 C sites.

RESULTS:

NSUN2 is highly expressed in PCa and predicts poor outcome. NSUN2 plays roles as a PCa oncogene both in vitro and in vivo. Depletion of NSUN2 results in decreased expression and activities of AR, including AR-V7. Mechanistically, NSUN2 posttranscriptionally stabilized AR by cluster m5 C modification in a m5CYBX1-dependent manner. Strikingly, treatment with enzalutamide, an effective AR inhibitor, reduces NSUN2 expression and decreases the m5C modification level in prostate cancer cells. Finally, we found that AR transcriptionally regulates NSUN2.

CONCLUSION:

NSUN2 stabilizes AR mRNA through cluster 5-methylcytosine modification and activates a positive feedback loop to promote prostate cancer.

• Authors: Wenkai Zhu, Fangning Wan, Wenhao Xu, Zheng Liu, Junjie Wang, Hena Zhang, Shenglin Huang, Dingwei Ye
• Journal: Clinical and translational medicine (Clin Transl Med) Vol. 12 Issue 9 Pg. e1028 (09 2022) ISSN: 2001-1326 [Electronic] United States
• PMID: 36169095 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Chemical References

• AR protein, human
• Androgen Antagonists
• Androgen Receptor Antagonists
• Androgens
• RNA, Messenger
• Receptors, Androgen
• 5-Methylcytosine
• Methyltransferases
• NSUN2 protein, human

Topics

• 5-Methylcytosine
• Androgen Antagonists (pharmacology, therapeutic use)
• Androgen Receptor Antagonists (pharmacology, therapeutic use)
• Androgens (metabolism, therapeutic use)
• Epigenesis, Genetic (genetics)
• Humans
• Male
• Methyltransferases (genetics, metabolism, therapeutic use)
• Prostatic Neoplasms, Castration-Resistant (drug therapy, genetics, pathology)
• RNA, Messenger
• Receptors, Androgen (chemistry, genetics, metabolism)